focus
Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.
The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.
advertisement
Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Inequities make cancer less preventable for women: report
Next article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Duchenne breakthrough therapy leaves behind pioneering families
.png?upscale=true&width=1212&upscale=true&name=vTFET-vaccine-makers-surge-on-bird-flu-fears(3).png)
